Ten patients with head trauma received an intravenous bolus of sufentanil (2 jg kg-1) followed at 30 min by infusion of sufentanil (median 150 jg h-1) and midazolam (median 9.0 mg h-1) over 48 h. Median (range) values of pharmacokinetic parameters for sufentanil were: tih,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-; Vss = 10.0 (6.8-24.2) 1 kg-. Decreases in intracranial pressure (ICP) (from 16.1 ± 1.7 to 10.8 ± 1.3 mm Hg; P < 0.05) and mean arterial blood pressure (MAP) (from 85.5 ± 3.9 to 80.2 ± 4.9 mm Hg; P < 0.05) were observed within 15 min of the bolus injection of sufentanil and remained unchanged thereafter. Thus, cerebral perfusion pressure (CPP = MAP-ICP) was stable.
Introduction
The pharmacokinetics of sufentanil in intensive care patients have not been documented in detail [1] . Although opioids are often administered to patients with severe head trauma, the effects of such drugs on cerebral haemodynamics and intracranial pressure (ICP) are controversial. Sufentanil has been reported to increase cerebral blood flow (CBF) and ICP in man and dogs [2] [3] [4] . In contrast, other studies in humans, rats and dogs indicate that sufentanil administration is associated with either no change or a decrease in CBF and ICP [5] [6] [7] [8] .
The aims of the present study were to describe the steady state pharmacokinetics of sufentanil and to assess its effects on ICP in patients with elevated ICP following brain injury.
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Methods
After obtaining institutional ethics review board approval and informed consent from family members, 10 brain-injured patients (three women and seven men; Glasgow Coma Scale < 6) were studied within 5 days of admission to the intensive care unit (ICU). Included in the study were patients with severe head trauma who presented diffuse bihemispheric brain oedema on computed tomography scan. Patients suffering from pulmonary, cardiovascular, hepatic or renal failure were excluded. The median (range) age, weight and height of the patients were 34 (10- Plasma and urine sufentanil concentrations were measured by radioimmunoassay (r.i.a.). The assay is specific for sufentanil and has a lower limit of determination of 0.1 ng ml-' [9] . Intra-and inter-assay coefficients of variation were 5.4 and 5.9%, respectively, over a range of 0.1 to 8.0 ng per assay tube. Plasma concentrations of midazolam were measured by a g.l.c. assay with electron-capture detection [10] . The assay has a lower limit of quantification of 5 ng ml-'. Intra-and inter-assay coefficients of variation were 5.1 and 5.8%, respectively, over a range of 10 to 100 ng ml-'.
Pharmacokinetic analysis
The individual plasma sufentanil concentrations following bolus injection (30 min), during continuous infusion (47.5 h) and post-infusion (48-72 h) were fitted simultaneously in a two compartment open model using the nonlinear least square regression programme TopFit [11] . Data points were weighted by the ratio l/y2. Total clearance (CL) and the volume of distribution at steady state (V,,) were calculated from the fitted data. In addition, the initial distribution following bolus injection was estimated from a separate fit over the first 30 min by the same programme.
The terminal elimination half-life (tlh,z) was calculated from the post-infusion data (4-24 h [12, 13] . In contrast, the terminal elimination half-life (16 h) was longer than reported after bolus administration (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) h) [14] [15] [16] [17] and the Vs, value (10 1 kg-') was higher (2-9 1 kg-') [14] [15] [16] [17] [18] [19] [20] [21] . These differences may be related to differences in the underlying disease states and to the duration of plasma sampling (24 h in our study). Also, the state of ventilation and a possible interaction between sufentanil and fentanyl may be considerations [12, 13] . The large variability in the pharmacokinetics of sufentanil in ICU patients may have implications for safe and effective dosage. Alazia et al. [1] reported lower steady state plasma sufentanil concentrations in ICU patients (0.28 ng ml-') than in the present study (1.50 ng ml-') but similar t'h2,z (15 ± 8 h) and V,, (15 ± 6 1 kg-') values (mean ± s.d., n = 8). The long terminal half-life observed in head trauma patients suggests that recovery from prolonged administration of sufentanil may be longer than would have been anticipated from previously published pharmacokinetic data based on i.v. bolus administration.
The clearance of midazolam was comparable with previous findings [22, 23] , indicating no modification by sufentanil.
Pharmacodynamics
The effects of opioids on central haemodynamics remain controversial, questioning in some instances their use in patients with increased ICP or compromised intracranial compliance. As in previous studies [24, 25] , a slight decrease in MAP was noted in the present study. The observed small decrease in ICP appeared to precede the change in MAP. Since CPP was stable throughout our study, the observed pharmacodynamic changes were not considered to be harmful to the patients. In earlier studies [2, 4] , a decrease in MAP may have been the primary cause of a reflex increase in ICP. The latter may result from an exponential increase in cerebral blood volume resulting from vasodilatation of brain areas with intact autoregulation. This happens when CPP decreases to less than 60 mm Hg. In accordance with Weinstabl et al. [7] , we conclude that sufentanil itself exerts no increase in ICP. Thus, concomitant haemodynamic changes should be monitored closely.
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